HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide

Multiple myeloma (MM) is a hematological malignancy of plasma cells in the bone marrow. Despite multiple treatment options, MM is inevitably associated with drug resistance and poor outcomes. Histone deacetylase inhibitors (HDACi's) are promising novel chemotherapeutics undergoing evaluation in...

Descripción completa

Detalles Bibliográficos
Autores principales: Canella, Alessandro, Nieves, Hector Cordero, Sborov, Douglas W., Cascione, Luciano, Radomska, Hanna S., Smith, Emily, Stiff, Andrew, Consiglio, Jessica, Caserta, Enrico, Rizzotto, Lara, Zanesi, Nicola, Stefano, Volinia, Kaur, Balveen, Mo, Xiaokui, Byrd, John C., Efebera, Yvonne A., Hofmeister, Craig C., Pichiorri, Flavia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741593/
https://www.ncbi.nlm.nih.gov/pubmed/26429859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741593/
https://www.ncbi.nlm.nih.gov/pubmed/26429859

Ejemplares similares